Lack of trans-activation function for Maedi Visna virus and Caprine arthritis encephalitis virus Tat proteins  by Villet, S.téphanie et al.
Lack of trans-activation function for Maedi Visna virus and Caprine
arthritis encephalitis virus Tat proteins
Ste´phanie Villet,a,* Claudine Faure,a Baya Amel Bouzar,b Thierry Morin,b Ge´rard Verdier,a
Yahia Chebloune,b and Catherine Legrasa
a UMR 5534 INRA/CNRS/UCBL, “Re´trovirologie Animale et Vecteurs Re´troviraux,” Centre de Ge´ne´tique Mole´culaire et Cellulaire,
Universite´ Claude Bernard, 43 Boulevard du 11 novembre 1918, Villeurbanne, 69622, France
b UMR 754 INRA/ENVL/UCBL, Re´trovirus et pathologie compare´e “Virologie Cellulaire, Mole´culaire et Maladies Emergentes,”
Universite´ Claude Bernard, Lyon-1 Batiment B, 50 avenue Tony Garnier, 69366 Lyon Cedex 07, France
Received 13 August 2002; returned to author for revision 16 October 2002; accepted 20 October 2002
Abstract
All lentiviruses contain an open reading frame located shortly upstream or inside of the env gene and encoding a small protein which
has been designated Tat. This designation was mainly with respect to the positional analogy with the first exon of the trans-activator protein
of the well studied human immunodeficiency virus type 1 (HIV-1). In this work we comparatively studied the trans- activation activity
induced by Tat proteins of the small ruminant Maedi Visna virus (MVV) of sheep and Caprine arthritis encephalitis virus (CAEV) of goats
on MVV and CAEV LTRs with that induced by the human lentivirus HIV-1 on its own LTR. The HIV-1 LTR alone weakly expresses the
reporter GFP gene except when the HIV-1 Tat protein is coexpressed, the GFP expression is increased 60-fold. In similar conditions only
minimal trans-activation increasing two- to three-fold the MVV and CAEV LTR activity was found with MVV Tat protein, and no
trans-activation activity was detected in any used cell type or with any virus strain when CAEV Tat was tested. These results indicate that
the small ruminant lentiviruses (SRLV) differ from the primate lentiviruses in their control of expression from the viral LTRs and put into
question the biological role of the encoded protein named “Tat.”
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Maedi Visna virus (MVV) and Caprine arthritis enceph-
alitis virus (CAEV) are members of the lentivirus genus that
belongs to the retrovirus family. MVV and CAEV cause
chronic progressive interstitial pneumonia, mastitis, arthri-
tis, and encephalitis in sheep and goats (Narayan and Cork,
1985; Sigurdsson, 1954; Sigurdsson and Palsson, 1958;
Sigurdsson et al., 1957). These inflammatory diseases are
the result of interactions between mononuclear cells and the
infected cells of monocyte/macrophage lineage, which were
shown to be the main infected target cells in vivo. Differ-
entiation of the monocyte into a macrophage is necessary to
stimulate MVV and CAEV virus expression (Gendelman et
al., 1985, 1986). Similar to other lentiviruses, MVV and
CAEV cause persistent infection. However, unlike the hu-
man, simian, and feline lentiviruses, MVV and CAEV do
not cause immune deficiency in their infected hosts and do
not infect the CD4 T-lymphocytes.
Their genomes contain genes encoding the structural
proteins Gag, Pol, and Env, and three additional regulatory
proteins Tat, Rev, and Vif. MVV and CAEV tat genes
encode 94 and 86 amino acid (aa) products. MVV Tat
protein, similar to HIV-1 Tat protein, was described as a
trans-activator protein which upregulates viral expression
via an increase of viral RNA synthesis (Hess et al., 1989)
and RNA stability (Gdovin and Clements, 1992). However,
this increase is very variable, between 1.6- (Gourdou et al.,
1989) and 46-fold activation (Gdovin and Clements, 1992),
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but lower than HIV-1 Tat trans-activation (100-fold) (Fein-
berg et al., 1991; Hauber et al., 1987). Moreover, the lack of
expression of this protein following deletion of its coding
sequences in CAEV-CO virus strain does not abolish the
virus replication and no significant difference was observed
between the wild-type and the CAEVTat virus (Harmache
et al., 1995).
Tat-mediated transcription activation was shown to be
dependent on the presence of AP-1 and AP-4 sites located in
the U3 region of MVV long terminal repeat (LTR) (Gdovin
and Clements, 1992). Although the proximal AP-1 site to
MVV TATA box promoter was identified to be the most
important element for transcription enhancement (Hess et
al., 1989), MVV Tat protein does not bind the AP-1 site
directly (Gdovin and Clements, 1992).
MVV Tat protein can be divided into the following three
domains: a N-terminal acidic and hydrophobic domain, a
central leucine-rich domain, and a C-terminal cysteine-rich
domain. Comparative analysis of MVV Tat mutants, and
search of cellular proteins interacting with Tat domains,
have shown that (i) the N-terminal acidic is an activator
domain (Carruth et al., 1994) and can interact in vitro with
TATA binding protein (TBP) (Morse et al., 1999); (ii) the
leucine-rich domain can interact in vitro with Fos- and
Jun-specific proteins of AP-1 sites, via leucine-zipper do-
main (Morse et al., 1999). The cysteine-rich domain could
be involved in protein dimerization.
CAEV Tat protein is structurally similar to MVV Tat
protein, with a 100% identity in the leucine- and cysteine-
rich domains; in contrast, the activation domain is very
divergent between the two proteins. It was shown that
CAEV Tat protein trans-activates viral LTR, but at a lower
level than MVV Tat protein’s viral LTR (Jackson et al.,
1991; Kalinski et al., 1994; Saltarelli et al., 1993).
Since it was shown that deletion of Tat in CAEV genome
has no effect on virus replication, we were interested to
determine if there is a correlation between the lack of
interaction with viral replication and the lack of trans-
activation. To test this hypothesis, we directly compared the
trans-activation with MVV, CAEV, and human immunode-
ficiency virus type 1 (HIV-1) Tat proteins in similar condi-
tions. The trans-activation was studied in various cell types
including cells from species different from sheep and goats,
and with Tat proteins from different MVV and CAEV
strains. Finally, we studied the subcellular localization of
MVV and CAEV Tat proteins.
Our results clearly show that MVV Tat protein can
upregulate two to three times MVV and CAEV LTR pro-
moters independently of used cell type or MVV strain,
although HIV-1 Tat protein can trans-activate its own LTR
60-fold in the same conditions. We could not observe an
increase of LTR expression by CAEV Tat protein, with any
used cell type or CAEV strain, and this absence of trans-
activation does not correlate with a lack of entry of CAEV
Tat protein into the cell nucleus.
Results
Comparison of basal activity of MVV, CAEV, HIV-1, and
CMV promoters
Four plasmids were constructed to study comparatively
the promoter basal activity of MVV, CAEV, and HIV
LTRs, with that of the CMV promoter (Fig. 1A). All these
plasmid constructs contain the green fluorescent protein
(GFP) reporter gene driven by (1) CMV viral promoter
(pCMV); (2) LTR sequences from MVV KV-1772 virus
(pLTR KV-1772); (3) LTR sequences from CAEV CO
strain (pLTR CO); or (4) LTR sequences from HIV-1 virus
(pLTR HIV).
Plasmid DNAs of these four constructs were introduced
by transfection into HeLa cells. At 48 hours posttransfec-
tion, samples of transfected cells were used to quantify the
GFP protein fluorescence level using the flow cytometry
(FACS) analysis. The results of this analysis show that the
basal activities of MVV and CAEV LTR promoters were
very high, since no significant difference was observed
between their fluorescence level and that of the constitutive
CMV promoter (Fig. 1B). Moreover, the basal promoter
activities of MVV and CAEV LTR sequences were found to
be much higher (30- to 40-fold) than that of HIV-1 LTR
sequences.
Comparison of trans-activation of MVV, CAEV, and
HIV-1 LTRs with Tat proteins
To define the optimal experimental conditions, we used
different amounts of pTat KV-1772 plasmid DNA to trans-
fect with the pLTR KV-1772 plasmid DNA in HeLa cells.
The data reported in Fig. 2B show that the best results were
obtained with 1 g of pTat KV-1772 plasmid DNA. To
quantify the trans-activation activity of Tat proteins of
MVV and CAEV on their corresponding viral LTR pro-
moter sequences, in comparison with the HIV-1 Tat/LTR
system, three plasmids containing Tat-coding sequences
isolated from these three viruses were constructed, pTat
KV-1772, pTat CO, and pTat HIV. These constructs contain
tat gene from MVV KV-1772, CAEV CO, and HIV-1
molecular clones, respectively, driven by the CMV pro-
moter. A control plasmid pTat lacking the tat gene was
also constructed (Fig. 2A).
HeLa cells were cotransfected with pLTR HIV-, pLTR
KV-1772-, or pLTR CO-expressing GFP reporter gene
driven by LTR promoter sequences (see Fig. 1A) and the
respective Tat-expressing plasmids or pTat control plas-
mid (Fig. 2A). The fluorescence intensity in cotransfected
cells was quantified by FACS analysis at 48 h posttransfec-
tion. The level of LTR trans-activation by its respective Tat
protein was determined following comparison of the fluo-
rescence intensity of cells cotransfected with p-LTR and
p-Tat plasmids to that cotransfected with pLTR and pTat
control plasmid.
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The data reported in Fig. 2B show that MVV KV-1772
Tat protein trans-activates two to three times MVV LTR,
while no significant trans-activation was observed with
CAEV Tat protein. In contrast, in similar conditions HIV-1
Tat protein was found to trans-activate at least 60-fold
HIV-1 LTR.
These results are in agreement with those reported in the
literature describing that MVV Tat protein trans-activates
more efficiently MVV LTR than CAEV Tat protein does,
but much less than HIV-1 Tat protein.
Cell type dependent Tat protein trans-activation of viral
LTRs
The murine NIH-3T3 and caprine TIGEF fibroblasts, the
human epithelial HeLa cells, and the ovine immortalized
4133 macrophages were cotransfected with pLTR and pTat
plasmid DNAs from each of MVV KV-1772 and
CAEV-CO infectious molecular clones, respectively. The
pTat plasmid was used as negative control. Analysis of the
intensity of fluorescence of GFP protein by FACS was used
to evaluate the trans-activation activity of MVV and CAEV
LTR by MVV and CAEV Tat proteins. The results are
reported in Fig. 3A and B.
While no trans-activation activity was observed with
CAEV-CO Tat protein on CAEV LTR in any of the used
cell type (Fig. 3A), the trans-activation activity of MVV
LTR by MVV KV-1772 Tat protein was found to upregu-
late 1.4 times in TIGEF cells and 2.2 times in NIH-3T3 cells
(Fig. 3B). This last result indicates that MVV Tat protein
may interact with cellular proteins from other species than
goat to increase the transcription activity level. Surprisingly,
the highest trans-activation activity of MVV Tat/LTR sys-
tem was found in the murine fibroblasts NIH-3T3 cell line,
Fig. 1. Basal activities of MVV KV-1772, CAEV CO, and HIV-1 viral promoters. (A) Structure of p-LTR plasmid constructs. These four plasmids contain
the GFP (green fluorescent protein) reporter gene driven by (1) CMV (Cytomegalovirus) virus promoter; (2) U3R sequence from 257 to 31 of MVV
KV-1772 LTR; (3) U3R sequence from289 to28 of CAEV-CO LTR; or (4) U3R sequence from458 to77 of HIV-1 LTR. The GFP coding sequences
were flanked downstream by the SV40 (Simian virus 40) polyadenylation sequences (pA). (B) The four plasmids pCMV, pLTR KV-1772, pLTR CO, and
pLTR HIV were transfected independently in human HeLa cells. Forty-eight hours posttransfection, the fluorescence intensity in cells was quantified by
FACS analysis. Histograms represent the average of five independent transfections. The activity of CMV promoter was used as internal control.
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and the use of the natural target host cells of these viruses:
macrophages (4133 ovine macrophage cell line) did not
result in an increase of the trans-activation activity. Inter-
estingly, the LTR trans-activation level seems to be in-
versely correlated to the promoter basal level since the
highest activation was seen in NIH-3T3 cells in which the
promoter basal activity was the weakest, and the weakest
activation was seen in TIGEF cells in which the promoter
basal activity was the highest.
Influence of viral LTR and tat gene origin on the trans-
activation level
To determine whether the low trans-activation activity of
MVV and CAEV Tat proteins was common in SRLV
strains, we extended our study to LTRs and Tat proteins
from various strains and isolates of MVV and CAEV in a
Tat/LTR system. New pLTR plasmid was constructed with
LTR from MVV LV1-KS1 strain in addition to pLTR KV-
Fig. 2. Tat trans-activation activity on respective LTR promoters. (A) Structure of p-Tat plasmid constructs. These four plasmids contain the tat coding
sequences from (1) MVV KV-1772; (2) CAEV CO; (3) HIV-1 strains; and (4) no tat gene, driven by the constitutive CMV (cytomegalovirus) virus promoter.
The tat gene is flanked downstream by the SV40 (Simian virus 40) polyadenylation sequences (pA). (B, C) HeLa cells were cotransfected either by (1) pLTR
KV-1772 and pTat KV-1772; (2) pLTR CO and pTat CO; (3) pLTR HIV and pTat HIV plasmids; or by these same pLTR plasmids and the pTat control
plasmid. Forty-eight hours later, transfected cells were submitted to FACS analysis to quantify the fluorescence intensity. The level of activation was
calculated by the ratio of fluorescence intensity of each cell line to that of the pTat control cell line (B, C). The values shown at the top of each bar represent
the value of activation over the basal LTR promoters. The data represent the mean value of at least three separate transfection experiments. The activities
of basal promoters (pTat control plasmid) were used as controls.
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1772 and pLTR CAEV-CO. New pTat plasmids were con-
structed with tat genes from MVV LV1-KS1 and Pe.01
strains in addition to pTat KV-1772, and tat gene from
CAEV 93017 and 664 strains in addition to pTat CAEV-CO
plasmid.
GFP-expressing plasmid DNAs under the transcriptional
control of MVV and CAEV LTR promoter sequences were
cotransfected with plasmids expressing either MVV or
CAEV tat genes, or the control pTat plasmid, into NIH-
3T3 cells. Transfected cells were studied by FACS analysis
as above described at 48 h posttransfection.
The results of this analysis clearly show a very high basal
activity of both CAEV and MVV LTR promoters. In addi-
tion, no significant difference was observed in terms of Tat
protein activity between the various strains (Fig. 4B). Tat
proteins from various strains of MVV trans-activate two- to
three-fold MVV or CAEV LTR promoters. In contrast to
these results, no trans-activation activity of CAEV Tat
Fig. 3. Cell type dependent Tat trans-activation of Viral LTR. (A) Murine NIH-3T3, human HeLa, ovine 4133, and caprine TIGEF cells were cotransfected
either with pLTR CO plasmid and pTat CO plasmid or with pLTR CO plasmid and pTat control plasmid. Forty-eight hours posttransfection, cells were
analyzed by flow cytometry to quantify the fluorescence intensity and to determine the level of activation by calculating the ratio of fluorescence intensity
of each cell line compared to that of the pTat control cell line. (B) The same experiment as in (A) was performed except that the plasmids were replaced
by pLTR KV-1772 and pTat KV-1772. The values shown at the top of each bar represent the fold activation over the basal LTR promoters. The data represent
the mean value of at least three separate transfection experiments. The activities of basal promoters (pTat control plasmid) were used as controls.
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Fig. 4. Analysis of the influence of LTR (A) or tat gene (B) origin on the trans-activation activity of MVV LTR by MVV Tat proteins. (A) Murine cells
NIH-3T3 were cotransfected with either pLTR KV-1772, pLTR LV1-1KS1, or pLTR CO as first plasmid, and pTat KV-1772 or pTat control as second
plasmid. Forty-eight hours later, the fluorescence intensity in transfected cells were analyzed and quantified by flow cytometry. The trans-activation level was
calculated by the ratio of fluorescence intensity of each cell line expressing Tat compared to that transfected with the pTat control. (B) Murine cells NIH-3T3
were cotransfected with pLTR KV-1772 as the first plasmid and either pTat KV-1772, pTat LV1-1KS1, pTat Pe1.01, pTat CO, pTat 93017, and pTat 664
or by pTat control as second plasmid. Forty-eight hours posttransfection, the fluorescence intensity in transfected cells was analyzed and quantified by flow
cytometry. The level of activation was calculated as in (A). The values shown at the top of each bar represent the value of activation over the basal LTR
promoters. The data represent the mean value of at least three separate transfection experiments. The activities of basal promoters (pTat control plasmid)
were used as internal controls.
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proteins on MVV LTR (Fig. 4B) or CAEV LTR was ob-
served (data not shown). To determine whether the absence
of CAEV Tat protein trans-activation activity is related to a
subcellular localization of Tat in cells, we analyzed the
protein localization in Tat-expressing cells.
Subcellular location of MVV and CAEV Tat proteins
In previous in vitro studies, it was shown that (i) MVV
Tat protein interacts with Jun protein via its leucine-rich
domain and with TBP protein via its activator domain
(Morse et al., 1999), and (ii) MVV Tat protein activator
domain was located in the NH2-terminal region of the
protein (Carruth et al., 1994, 1996). In contrast however,
there are no data demonstrating such interactions in cell-
culture conditions. Minimal studies were reported up-to-
date for the trans-activation activity of CAEV Tat protein,
but considering the very high homology between MVV and
CAEV, the results obtained for MVV virus were often
transposed to CAEV.
However, the difference of LTR trans-activation activity
between MVV and CAEV Tat proteins and the nucleotide
divergence in their activator domain pushes us to consider
these two proteins independently. We therefore have com-
paratively studied the cellular localization of these two
proteins to investigate whether both Tat proteins enter
equally in the nucleus.
The Flag epitope was used to generate fusion proteins in
the NH2-terminal positions of MVV KV-1772 and CAEV
CO Tat molecules named pTat MVV-Flag and pTat CO-
Flag, respectively. The activity of pTat MVV-Flag was
found to be unchanged compared to that of the nonfused
pTat MVV (data not shown). Plasmid DNAs expressing
pTat MVV-Flag and pTat CO-Flag were used to transfect
NIH-3T3 cells in parallel with a control plasmid pTat
(without tat gene) used as negative control. Western blot
analysis using antibody directed against Flag epitope was
performed on the different protein extracts at 48 h posttrans-
fection (Fig. 5A). To exclude the possibility that the protein
localization is due to the Flag epitope, a similar experiment
was performed using plasmid DNA expressing MVV KV-
1772 native Tat protein, and a specific antibody directed
against a MVV Tat protein epitope was used (Fig. 5B).
The results of this analysis show that both MVV and
CAEV Tat proteins were found to be mainly in a nuclear
localization. Therefore, the absence of LTR trans-activation
by CAEV Tat protein cannot be explained by an inability of
this protein to penetrate into the nucleus.
Discussion
Our main aim in this study was to determine whether the
genetically well-conserved MVV and CAEV Tat coding
sequences have an effective role in trans-activating their
respective viral LTRs. As expected, our comparative study
clearly showed that MVV and CAEV Tat proteins trans-
activate their viral LTR at a very weak level compared to
HIV-1 Tat protein’s viral LTR. One of the explanations
could be the very high basal activity of MVV and CAEV
LTR promoters since it reaches the activity level of the
well-known constitutive CMV promoter and is at least 40
times higher than that to HIV-1 LTR promoter. One can
suppose that the trans-activation by MVV or CAEV Tat
Fig. 5. Cellular localization of MVV and CAEV Tat proteins. (A) Murine fibroblasts NIH-3T3 were transfected with pTat control plasmid (lanes 1 and 4),
pTat MVV-Flag plasmid (lanes 2 and 5), or pTat CO-Flag plasmid (lanes 3 and 6). Forty-eight hours posttransfection, cytoplasmic (lanes 1 to 3) and nuclear
(lanes 4 to 6) protein extracts were isolated and then detected by Western blot analysis using a monoclonal antibody directed against Flag epitope (10,000
dilution), and a second antibody directed against murine IgG (3000 dilution). (B) Murine fibroblasts NIH-3T3 were transfected with the pTat control
plasmid (lanes 1 and 3) or pTat KV-1772 plasmid (lanes 2 and 4). Forty-eight hours posttransfection, cytoplasmic (lanes 1 and 2) and nuclear (lanes 3 and
4) protein extracts were obtained and then detected by Western blot analysis using a rabbit polyclonal antibody anti-Tat (20,000 dilution), and a second
goat antibody directed against rabbit IgG (10,000 dilution).
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proteins is not yet possible as a consequence of expression
level saturation. To evaluate this hypothesis, it would be of
interest to study the trans-activation activity of MVV and
CAEV Tat proteins in a cell type weakly expressing MVV
and CAEV LTR promoters, or use LTR mutants that have a
weak basal promoter activity. However, in all the cells we
tested from various animal species and cells described in the
literature, MVV and CAEV promoters are expressed at a
very high level.
To determine whether the weak trans-activation activity
observed for these proteins was not the consequence of an
isolated case, we used LTR and Tat proteins from different
MVV and CAEV strains in the Tat/LTR system. The use of
these various strains helped us to analyze the influence of
viral LTR trans-activation level with respect to the LTR
promoter sequences or Tat protein origin.
We used promoter sequences from two MVV molecular
clones LV1-1KS1 (Staskus et al., 1991) and KV-1772 (An-
dresson et al., 1993) and from a CAEV isolate, CO isolate
(Saltarelli et al., 1990). It is interesting to note that the
LV1-1KS1 is poorly pathogenic in vivo, while in contrast
the KV-1772 strain was isolated for its neurovirulence.
Moreover, the LV1-1KS1 replicated with a virus titer 2 log
lower than that of KV-1772 in macrophage cultures (Tor-
steinsdottir et al., 1997). Sequence comparison of these two
molecular clones reveals 1% divergence in nucleotides with
2 mutations in gag, 9 in pol, 12 in env, 3 in vif, 4 in tat, and
5 in rev genes.
In viral LTR, three mutations differentiate LV1-KS1
from KV-1772 molecular clones. Two of these mutations
affect the integrity of AP-1 site present in the U3 sequences.
Similar to MVV K1514 the MVV prototype molecular
clone, this AP-1 site (TGAGTCA) is located in MVV LV1-
KS1 LTR at position 52. This sequence was found to be
mutated (G to A), transforming the canonic sequence
(TGAGTCA) to (TAAGTCA) in MVV KV-1772 LTR;
simultaneously, a canonic sequence was generated at posi-
tion 75. In the LTR of CAEV CO strain, no canonic but
only some putative AP- 1 site sequences (such as the se-
quence in the position 52 (TGCTCA)) were identified.
These three promoter sequences exhibit many differences in
both the content and the location of their AP-1 sites, which
have been shown to be essential for viral LTR trans-acti-
vation by MVV Tat protein (Gdovin and Clements, 1992).
Since MVV Tat protein trans-activates CAEV LTR at the
same level as MVV viral LTR (Fig. 4A), these data suggest
that these AP1 sites are not essential for the trans-activation
activity of MVV Tat protein.
To determine whether SRLV Tat proteins trans-activate
viral LTRs, we selected tat genes from three MVV (LV1-
1KS1, KV-1772, and Pe101) and three CAEV strains (CO,
93017, and 664). Tat proteins of all these viral strains were
100% identical in the leucine-rich and the cysteine-rich
domains, except for one mutation that substitutes a leucine
by an isoleucine in the CAEV664 strain.
The activator domains are relatively well conserved
among MVV strains despite the mutation of one phenylal-
anine that has been previously described to be more or less
important for viral LTR trans-activation, depending on the
cell type used (Carruth et al., 1994, 1996). On the other
hand this activator domain is very different between MVV
and CAEV Tat proteins. CAEV Tat protein activator do-
main does not contain the phenylalanine here abovemen-
tioned. The results of our study indicate that this amino acid
is not critical for the activity of MVV Tat protein since
MVV KV-1772 protein, lacking this phenylalanine residue,
trans-activates the LTRs at the same level as MVV LV1-
1KS1 Tat protein does (Fig. 4B). MVV LV1-1KS1 strain,
known to induce weak pathogenesis in infected sheep,
showed neither a lower LTR basal level (Fig. 4A) nor a
lower Tat protein trans-activation activity (Fig. 4B). There-
fore these data exclude the relationship between the trans-
activation of LTR and the severity of induced pathogenesis.
Interestingly, none of the tested CAEV Tat proteins in-
duced trans-activation of SRLV LTR promoters. This data
indicate that the absence of trans-activation activity of
CAEV Tat is common to many strains. In addition, our data
demonstrated that the lack of this trans-activation activity of
CAEV Tat proteins does not correlate with the inability of
this protein to enter in the nucleus of Tat-expressing cells.
Altogether these data suggest that the primary function
of these SRLV Tat proteins is not to trans-activate the viral
LTR promoters as Tat proteins from others lentiviruses do
(Cullen, 1992). EIAV (Albrecht et al., 2000), BIV (Barboric
et al., 2000), SIV (Viglianti and Mullins, 1988), and HIV
(Luo et al., 1993) Tat proteins were shown to have similar
interactions with their target sequences, by attachment on
TAR sequences (attachment site for Tat protein). In con-
trast, in MVV or CAEV LTRs no TAR sequence was
identified. These data suggest that the LTR promoters of
SRLV look to be Tat-independent. The lack of TAR se-
quence in FIV LTR suggests also that FIV Tat protein may
act similar to SRLV Tat proteins (de Parseval and Elder,
1999).
To date, the biological role of SRLV Tat protein still
remains unclear, and the only well-defined property is that
SRLV Tat protein is not essential for efficient virus repli-
cation (Harmache et al., 1995). Since Tat is dispensable for
virus replication for small ruminant lentiviruses, we specu-
late that this protein is rather an accessory than a regulator
protein, as was previously suggested (Cullen, 1992). Further
experiments must be done to help to better define the bio-
logical functions of these well-conserved open reading
frames.
Materials and methods
Plasmid construction
pLTR plasmids were constructed by inserting the U3
promoter sequences from MVV and CAEV, and the U3R
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sequences from HIV-1 in replacement of the SV40 pro-
moter into the EcoRI and XhoI sites of pGFPemd-p pro-
moter (Packard). U3 sequences were amplified from pLV1-
RS1 plasmid (Staskus et al., 1991) for LV1-KS1 U3 region
and p8Xsp5-RK1 plasmid (Andresson et al., 1993) for KV-
1772 U3 region using V3 and V5 primers, and from pK9 Kb
(Mselli-Lakhal et al., 2000; Turelli et al., 1996) plasmid for
CAEV-CO U3 region using C3 and C5 primers. U3R se-
quences were amplified from pLTR HIV-CAT plasmid
(kindly provided by L. Gazzolo) using U3-HIV-1 and R-
HIV-1 primers.
The nucleotide sequences of used oligonucleotide prim-
ers are presented here as follows: V3: 5 TGAATTC-
GAGCTCTCCAAAG 3; V5: 5 TCTCGAGTGGACTGT-
CAGGAC 3; C3: 5 GGAATTCGAGACTAGGAGGGAC
3; C5: 5 TCCTCGAGTGACTGTGAGACATGG 3; U3-
HIV-1: 5 GCTCGAGGAAGGGCTAATTCACT 3;
R-HIV-1: 5 GGAATTCTATTGAGGCTTAAGCAG 3.
pTat plasmids contain the CMV promoter, the tat gene from
various MVV and CAEV strains or HIV- 1 tat gene, and the
simian virus 40 polyadenylation signals cloned into BSK,
BSK-CMV was obtained by inserting a 633-bp BgIII-to-
PstI fragment of the CMV promoter from pUT535 plasmid
(Cayla) into BamHI and PstI sites of BSK, BSK-CMV-pA
was created by inserting a 158-bp SaII-ApaI fragment of the
SV40 polyadenylation signal isolated from pUT614 plasmid
(Cayla) into BSK-CMV. BSKtat plasmids were constructed
by inserting the tat gene from various strains of MVV,
CAEV or HIV-7 after PCR amplification using primers de-
scribed below into EcoRI-HindIII sites of BSK-CMV-pA.
MVV LV1-KS1 tat gene was amplified from pLV1-RS1
and MVV KV-1772 from p8XSp5RK1, using TAT01 and
TAT02 primers, as follows: TAT01: 5 GGAATTCTGCAG
GAATGCTGGGAAA 3; TAT02: 5 CCAAGCTTATCA-
CAGTTCAACATT TC 3. CAEV CO tat gene was ampli-
fied from pK9 kb using TAT03 and TAT04 primers:
TAT03: 5 GGAATTCCAGGAGTGCTGGTTGATG 3.
TAT04: 5 CCAAGCTTGATTATGTTCCC CACCC 3.
MVV Pel.01 tat gene was amplified from pPe1–01 (Castro
et al., 1999) using BR5 and BR3 primers: BR5: 5 GGAAT-
TCGTATGGAATCAATAT 3; BR3: 5 CCAAGCTT-
TACGTTCTCCATC 3. CAEV 93017 tat gene was ampli-
fied from p93017–02 (Castro et al., 1999) using 93017–5
and 93017–3 primers: 93017–5: 5 GGAATTCTTGAAT-
ACCTAT 3; 93017–3: 5 AAAAGCTTGATTATGT-
TCCC 3, CAEV-like 664 tat gene was amplified from
p664–03 (Castro et al., 1999) using 664–5 and 664-3 prim-
ers: 664–5: 5 GGAATTCAAGCGTGGACAA 3; 664-3:
5 GCAAGCTTGATTATGTTCCC 3. HIV-1 tat gene was
obtained from pSG5Tat plasmid kindly provided by L.
Gazzolo after EcoRI-BamHI digest and filled by the Klenow
large fragment of DNA polymerase. This fragment, contain-
ing two exons from HIV-1 tat gene coding for 86 aa protein,
was then inserted into EcoRI-HindIII sites of BSK-
CMV-pA plasmid.
pTat MVV-Flag and pTat CO-Flag plasmids contain tat
gene from MVV KV-1772 and CAEV CO strains, respec-
tively, fused to the Flag epitope. To generate the fusion
between tat gene from MVV or CAEV and the Flag epitope,
tat sequence was amplified by PCR from p8XSp5RK1 plas-
mid for MVV and from pK9 Kb plasmid for CAEV, using
a primer already containing the flag sequence, named V-
Flag5 and C-Flag5, respectively, and a second primer, as
above described and named TAT02 and TAT04, respec-
tively: V-Flag5: 5GGAATTCATGGACTACAAGGAC-
GACGATGACAAGGAAGAAGTACCAAGAAGACAGC-
CAGGAGGCTTAGTAGAAGTAGAGGGAGTATTTC-
AATTTTATGAAGA 3; C-Flag5: 5GGAATTCATG-
GACTACAAGGACGACGATGACAGTGAAGAACTG-
CCTCAAAGAAGGGAGACACATCCAGAAGAACTT-
GTAAGGAACGTACGGGAAAGAGAAAG 3. The ob-
tained PCR products containing the Tat-Flag fusions were then
inserted between EcoRI and HindIII sites of BSK-CMV-pA
plasmid to generate pTat MVV-Flag and pTat CO-Flag plas-
mids.
Cells
Murine embryo fibroblasts NIH-3T3 and human epithe-
loid carcinoma HeLa cells were maintained in DMEM me-
dium supplemented with 10% fetal calf serum and incu-
bated at 5% CO2 at 37°C. Large T immortalized goat
embryo fibroblasts (TIGEF) (Da Silva Teixeira et al., 1997)
were maintained in MEM medium supplemented with 10%
fetal calf serum. Immortalized ovine macrophages 4133
(Olivier et al., 2001) were maintained in RPMI 1640 me-
dium supplemented with 10% fetal calf serum.
Transfection procedures
To assay Tat-mediated trans-activation, cell lines were
plated in six-well cluster dishes at a density of 2  105 cells
per well 24 h before transfection. TIGEF, NIH-3T3, and
4133 cells were transfected by the Fugene-6 method
(Roche) and used according to the manufacturer’s instruc-
tions. Plasmid DNAs (pTat: 1 g, pLTRs: 1 g) were
mixed with 6 l fugene in optimem serum-free medium.
The DNA-fugene sample was allowed to incubate for 15
min at room temperature and was added to the cell mono-
layer. HeLa cells were transfected by the effectene method
(Qiagen) and used according to the manufacturer’s instruc-
tions. Four microliters of enhancer was added to the
DNA-EB buffer sample and incubated for 3 min at room
temperature. Then 5 l of effectene reagent was mixed with
the DNA-enhancer sample and incubated for an additional
10 min at room temperature before adding to cells. Medium
was changed 5 h after transfection.
Analysis of transfected cells
Forty eight hours posttransfection, cells were dissociated
by trypsin treatment and analyzed by flow cytometry. Cell
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fluorescence levels were determined by FACScan and the
data analyzed by using the Cell Quest program (Becton–
Dickinson). Each transfection was done in duplicate and
repeated two to five times with at least three different
plasmid preparations to ensure the reproducibility of the
results. To avoid fluorescence saturation, a scale was per-
formed with different amounts of plasmids and an equiva-
lent quantity (1 g) of pLTR and pTat plasmids was re-
tained.
Protein extracts and Western blot analysis
For Western blot analysis, cells were harvested 48 h
posttransfection.
For total protein extracts, cells were scraped in 1 ml 1
PBS and then centrifuged for 10 s at 10,000 rpm and pellets
were resuspended into 50 l 1 PBS. Protein extracts were
incubated at20°C before quantification by Bradford assay
(Bio-Rad) and gel analysis.
For cytoplasmic and nuclear extracts, cells were disso-
ciated by trypsin, washed with 1 PBS, resuspended in 200
l of A lysis solution (HEPES pH 7.9 10 mM; MgCl2 1.5
mM; KCl 10 mM; NP-40 0.1%; protease inhibitor 50 l/ml;
DTT 0.5 mM; ZnCl2 0.1 mM), and then ice-incubated for 15
min. The resulting solution was centrifuged for 1 min at
12,000 rpm, and the supernatant was named the cytoplasmic
fraction. Fifty microliters of B lysing solution was added to
the pellet and the mixture was incubated for 45 min at 4°C
before centrifugation for 15 min at 12,000 rpm. The super-
natant was called the nuclear fraction.
Proteins from cell lysates were separated on a sodium
dodecyl sulfate (SDS)–16.5 polyacrylamide gel. MVV Tat
protein and Flag fusion Tat proteins were detected by using
a rabbit polyclonal antiserum specific to Visna virus Tat and
a monoclonal antibody directed against flag epitope, respec-
tively. Blots were developed by enhanced chemilumines-
cence (ECL kit; Amersham, France) according to the man-
ufacturer’s instructions.
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